Recent developments in immunotherapy are improving treatment results of B-precursor acute lymphoblastic leukemia. This advancement is promoted by new monoclonal antibodies such as inotuzumab ozogamicin, ofatumumab and blinatumomab, by rituximab, and by genetically engineered chimeric antigen receptor-modified T-cells. These treatments, variously targeting CD22, CD20 and CD19 antigens, yield unprecedented high rates of hematologic and molecular remissions even when used in monotherapy and in chemo-resistant or post-transplantation relapsed patients. Beside the encouraging results in relapsed/refractory disease, these agents may open a totally new era in the frontline management of this illness, redefining treatment standards and options for ...
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a challenging pediatric and adult haematolog...
Abstract Refractory/relapsed B-cell acute lymphoblastic leukemia remains to be a significant cause o...
Immunotherapy is the most rapidly evolving field in clinical malignant hematology. Targeting of the ...
The introduction of newer cytotoxic monoclonal antibodies and the chimeric antigen receptor-modified...
Patients with acute lymphoblastic leukemia (ALL) are characterized by an unfavorable outcome in the ...
Patients with acute lymphoblastic leukemia (ALL) are characterized by an unfavorable outcome in the ...
Mark R LitzowMayo Clinic, Rochester, MN, USAAbstract: Acute lymphoblastic leukemia (ALL) arises from...
Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic hematopo...
Abstract. The introduction of newer cytotoxic monoclonal antibodies and chimeric antigen receptor mo...
Abstract The relapse rate remains high after chemotherapy for adult patients with acute lymphoblasti...
B cell-specific antigens such as CD20 and CD19 are the leading examples of clinically utilized targe...
The treatment of acute myeloid leukemia (AML) did not evolve profoundly in the last decades. Some im...
Chemotherapy has been dominating the field of cancer treatment for a long time, however, its limitat...
The efficacy of immunotherapeutic approaches in the treatment of different cancer types is becoming ...
Natalie Uy, Michelle Nadeau, Maximilian Stahl, Amer M Zeidan Section of Hematology, D...
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a challenging pediatric and adult haematolog...
Abstract Refractory/relapsed B-cell acute lymphoblastic leukemia remains to be a significant cause o...
Immunotherapy is the most rapidly evolving field in clinical malignant hematology. Targeting of the ...
The introduction of newer cytotoxic monoclonal antibodies and the chimeric antigen receptor-modified...
Patients with acute lymphoblastic leukemia (ALL) are characterized by an unfavorable outcome in the ...
Patients with acute lymphoblastic leukemia (ALL) are characterized by an unfavorable outcome in the ...
Mark R LitzowMayo Clinic, Rochester, MN, USAAbstract: Acute lymphoblastic leukemia (ALL) arises from...
Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic hematopo...
Abstract. The introduction of newer cytotoxic monoclonal antibodies and chimeric antigen receptor mo...
Abstract The relapse rate remains high after chemotherapy for adult patients with acute lymphoblasti...
B cell-specific antigens such as CD20 and CD19 are the leading examples of clinically utilized targe...
The treatment of acute myeloid leukemia (AML) did not evolve profoundly in the last decades. Some im...
Chemotherapy has been dominating the field of cancer treatment for a long time, however, its limitat...
The efficacy of immunotherapeutic approaches in the treatment of different cancer types is becoming ...
Natalie Uy, Michelle Nadeau, Maximilian Stahl, Amer M Zeidan Section of Hematology, D...
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a challenging pediatric and adult haematolog...
Abstract Refractory/relapsed B-cell acute lymphoblastic leukemia remains to be a significant cause o...
Immunotherapy is the most rapidly evolving field in clinical malignant hematology. Targeting of the ...